Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: An analysis from the women, integrase, and fat accumulation trial

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Hulgan, Todd ^a   Boger, M Sean ^b   Liao, Diana H ^c   McComsey, Grace A ^d   Wanke, Christine A ^e   Mangili, Alexandra ^e   Walmsley, Sharon L ^f   McCreath, Heather ^c   Milne, Ginger L ^a   Sanchez, Stephanie C ^a   Currier, Judith S ^c   Lake, Jordan E ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e TUFTS UNIVERSITY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSANOID; ISOPROSTANE DERIVATIVE; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN E2; PROTEINASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; THROMBOXANE B2; 2 PYRROLIDONE DERIVATIVE; INTEGRASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BODY WEIGHT; CENTRAL OBESITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIP CIRCUMFERENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; NECK CIRCUMFERENCE; OBESITY; PRESCRIPTION; SMOKING; SUBCUTANEOUS FAT; TREATMENT DURATION; URINALYSIS; URINE LEVEL; ABDOMINAL OBESITY; CROSS-SECTIONAL STUDY; HIV INFECTIONS; METABOLISM; MIDDLE AGED; URINE;

ADULT; CROSS-SECTIONAL STUDIES; EICOSANOIDS; FEMALE; HIV INFECTIONS; HUMANS; INTEGRASES; MIDDLE AGED; OBESITY, ABDOMINAL; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84903650078     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/803095     Document Type: Article

References (58)

1. Carr A., HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003 17 1 S141 S148 2-s2.0-0038204340 (Pubitemid 36667790)
2. Haubrich R. H., Riddler S. A., Dirienzo A. G., Komarow L., Powderly W. G., Klingman K., Garren K. W., Butcher D. L., Rooney J. F., Haas D. W., Mellors J. W., Havlir D. V., Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009 23 9 1109 1118 2-s2.0-67651096095 10.1097/QAD.0b013e32832b4377
3. Health K. V., Chan K. J., Singer J., O'Shaughnessy M. V., Montaner J. S. G., Hogg R. S., Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. International Journal of Epidemiology 2002 31 5 1016 1020 2-s2.0-0036816912 (Pubitemid 35446877)
4. Cabrero E., Griffa L., Burgos A., Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions. AIDS Patient Care and STDs 2010 24 1 5 13 2-s2.0-76649142396 10.1089/apc.2009.0191
5. Currier J., Scherzer R., Bacchetti P., Heymsfield S., Lee D., Sidney S., Tien P. C., Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes 2008 48 1 35 43 2-s2.0-42649088058 10.1097/QAI.0b013e318164227f (Pubitemid 351600850)
6. Wohl D., Scherzer R., Heymsfield S., Simberkoff M., Sidney S., Bacchetti P., Grunfeld C., The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. Journal of Acquired Immune Deficiency Syndromes 2008 48 1 44 52 2-s2.0-42649088057 10.1097/QAI.0b013e31816d9ba1 (Pubitemid 351600858)
7. Grunfeld C., Kotler D. P., Arnett D. K., Falutz J. M., Haffner S. M., Hruz P., Masur H., Meigs J. B., Mulligan K., Reiss P., Samaras K., Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008 118 2 e20 e28 2-s2.0-47649092908 10.1161/ CIRCULATIONAHA.107.189623
8. Falutz J., HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies. Current Opinion in Clinical Nutrition and Metabolic Care 2011 14 3 255 260 2-s2.0-79955024117 10.1097/MCO.0b013e3283457a8f
9. Johnson J. A., Albu J. B., Engelson E. S., Fried S. K., Inada Y., Ionescu G., Kotler D. P., Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. American Journal of Physiology, Endocrinology and Metabolism 2004 286 2 E261 E271 2-s2.0-0942265682 (Pubitemid 38140318)
10. Neuhaus J., Jacobs D. R. Jr., Baker J. V., Calmy A., Duprez D., Rosa A. L., Kuller L. H., Pett S. L., Ristola M., Ross M. J., Shlipak M. G., Tracy R., Neaton J. D., Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. Journal of Infectious Diseases 2010 201 12 1788 1795 2-s2.0-77952571995 10.1086/652749
11. Torriani F. J., Komarow L., Parker R. A., Cotter B. R., Currier J. S., Dubé M. P., Fichtenbaum C. J., Gerschenson M., Mitchell C. K. C., Murphy R. L., Squires K., Stein J. H., Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. The ACTG (AIDS Clinical Trials Group) study 5152s. Journal of the American College of Cardiology 2008 52 7 569 576 2-s2.0-48449086593 10.1016/j.jacc.2008.04.049
12. Law M. G., Friis-Møller N., El-Sadr W. M., Weber R., Reiss P., D'Arminio Monforte A., Thiébaut R., Morfeldt L., De Wit S., Pradier C., Calvo G., Kirk O., Sabin C. A., Phillips A. N., Lundgren J. D., Collins S., Mertenskoetter E., Loeliger R., Tressler R., Weller I., Sawitz A., Rickenbach M., Pezzotti P., Krum E., Gras L., Lavignolle V., Sundströrm A., Poll B., Fontas E., Torres F., Petoumenos K., Kjær J., The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Medicine 2006 7 4 218 230 2-s2.0-33645467423 10.1111/j.1468-1293.2006.00362.x
13. Parra S., Coll B., Aragonés G., Marsillach J., Beltrán R., Rull A., Joven J., Alonso-Villaverde C., Camps J., Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Medicine 2010 11 4 225 231 2-s2.0-77950805699 10.1111/j.1468-1293.2009.00766.x
14. Morrow J. D., Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 2 279 286 2-s2.0-13244279737 10.1161/01.ATV.0000152605. 64964.c0 (Pubitemid 40189146)
15. Milne G. L., Yin H., Brooks J. D., Sanchez S., Jackson Roberts L. II, Morrow J. D., Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods in Enzymology 2007 433 113 126 2-s2.0-38449117165 10.1016/S0076-6879(07)33006-1
16. Milne G. L., Morrow J. D., Isoprostanes and related compounds: update 2006. Antioxidants and Redox Signaling 2006 8 7-8 1379 1384 2-s2.0-33746844146 10.1089/ars.2006.8.1379 (Pubitemid 44182435)
17. Pratico D., Dogne J. M., Vascular biology of eicosanoids and atherogenesis. Expert Review of Cardiovascular Therapy 2009 7 9 1079 1089 10.1586/erc.09.91
18. Morrow J. D., Minton T. A., Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 1993 612 2 179 185 2-s2.0-0027476693 (Pubitemid 23067174)
19. Murphey L. J., Williams M. K., Sanchez S. C., Byrne L. M., Csiki I., Oates J. A., Johnson D. H., Morrow J. D., Quantification of the major urinary metabolite of PGE 2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE 2 synthesis in healthy humans and those with lung cancer. Analytical Biochemistry 2004 334 2 266 275 2-s2.0-5644272862 10.1016/j.ab.2004.08.019 (Pubitemid 39370961)
20. Daniel V. C., Minton T. A., Brown N. J., Nadeau J. H., Morrow J. D., Simplified assay for the quantification of 2,3-dinor-6-ketoprostaglandin F1 α by gas chromatography-mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 1994 653 2 117 122 2-s2.0-0028328581 (Pubitemid 24085049)
21. Dorjgochoo T., Gao Y.-T., Chow W.-H., Shu X.-O., Yang G., Cai Q., Rothman N., Cai H., Li H., Deng X., Franke A., Roberts L. J., Milne G., Zheng W., Dai Q., Major metabolite of F2-isoprostane in urine may be a more sensitive biomarker of oxidative stress than isoprostane itself. American Journal of Clinical Nutrition 2012 96 2 405 414 2-s2.0-84864349291 10.3945/ajcn.112.034918
22. Wu X., Cai H., Xiang Y.-B., Cai Q., Yang G., Liu D., Sanchez S., Zheng W., Milne G., Shu X.-O., Intra-person variation of urinary biomarkers of oxidative stress and inflammation. Cancer Epidemiology Biomarkers and Prevention 2010 19 4 947 952 2-s2.0-77950819459 10.1158/1055-9965.EPI-10-0046
23. Schwedhelm E., Bartling A., Lenzen H., Tsikas D., Maas R., Brümmer J., Gutzki F.-M., Berger J., Frölich J. C., Böger R. H., Urinary 8-iso-prostaglandin F2 α as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004 109 7 843 848 2-s2.0-10744230298 10.1161/01.CIR.0000116761.93647.30 (Pubitemid 38252735)
24. Basarici I., Altekin R. E., Demir I., Yilmaz H., Associations of isoprostanes-related oxidative stress with surrogate subclinical indices and angiographic measures of atherosclerosis. Coronary Artery Disease 2007 18 8 615 620 2-s2.0-40349092911 10.1097/MCA.0b013e3282f0efa5 (Pubitemid 351339514)
25. Martino F., Loffredo L., Carnevale R., Sanguigni V., Martino E., Catasca E., Zanoni C., Pignatelli P., Violi F., Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamide-adenine dinucleotide phosphate oxidase. Pediatrics 2008 122 3 e648 e655 2-s2.0-51649094903 10.1542/peds.2008-0735
26. Araki S., Dobashi K., Yamamoto Y., Asayama K., Kusuhara K., Increased plasma isoprostane is associated with visceral fat, high molecular weight adiponectin, and metabolic complications in obese children. European Journal of Pediatrics 2010 169 8 965 970 2-s2.0-77954425922 10.1007/s00431-010-1157-z
27. 2 are increased in smokers. Clinical Cancer Research 2005 11 16 6087 6093 2-s2.0-23844555182 10.1158/1078-0432.CCR-05-0733 (Pubitemid 41170341)
28. 2-isoprostanes) in smokers: Smoking as a cause of oxidative damage. The New England Journal of Medicine 1995 332 18 1198 1203 2-s2.0-0029002677
29. 2 and prostacyclin metabolites in women stratified by age. Circulation 1992 86 5 1495 1500 2-s2.0-0026487859
30. 2 and prostacyclin in cigarette smokers. Circulation 2005 112 7 1024 1029 2-s2.0-23844442838 10.1161/CIRCULATIONAHA.105.542696 (Pubitemid 41170271)
31. McComsey G. A., Morrow J. D., Lipid oxidative markers are significantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia. Journal of Acquired Immune Deficiency Syndromes 2003 34 1 45 49 2-s2.0-0042916024 10.1097/00126334-200309010-00006 (Pubitemid 37100110)
32. Hulgan T., Morrow J., D'Aquila R. T., Raffanti S., Morgan M., Rebeiro P., Haas D. W., Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clinical Infectious Diseases 2003 37 12 1711 1717 2-s2.0-0346848715 10.1086/379776 (Pubitemid 37549961)
33. Boger M. S., Bian A., Shintani A., Milne G. L., Morrow J. D., Erdem H., Mitchell V., Haas D. W., Hulgan T., Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy. Antiviral Therapy 2012 17 3 485 493 2-s2.0-84861709241 10.3851/IMP1990
34. 2-isoprostane levels in HIV-infected adults. HIV Clinical Trials 2009 10 3 181 192 2-s2.0-69249131696 10.1310/hct1003-181
35. Glesby M. J., Hoover D. R., Raiszadeh F., Lee I., Shi Q., Milne G., Sanchez S. C., Gao W., Kaplan R. C., Morrow J. D., Anastos K., Oxidant stress in HIV-infected women from the Women's Interagency HIV Study. Antiviral Therapy 2009 14 6 763 769 2-s2.0-72049123481 10.3851/IMP1290
36. 2 levels. Cancer Prevention Research 2012 5 1 34 40 2-s2.0-84862907776 10.1158/1940-6207.CAPR-11-0496
37. Eron J. J., Cooper D. A., Steigbigel R. T., Clotet B., Gatell J. M., Kumar P. N., Rockstroh J. K., Schechter M., Markowitz M., Yeni P., Loutfy M. R., Lazzarin A., Lennox J. L., Strohmaier K. M., Wan H., Barnard R. J., Nguyen B.-Y. T., Teppler H., Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. The Lancet Infectious Diseases 2013 13 7 587 596 2-s2.0-84879799713 10.1016/S1473-3099(13)70093-8
38. Lennox J. L., DeJesus E., Lazzarin A., Pollard R. B., Madruga J. V. R., Berger D. S., Zhao J., Xu X., Williams-Diaz A., Rodgers A. J., Barnard R. J., Miller M. D., DiNubile M. J., Nguyen B.-Y., Leavitt R., Sklar P., Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. The Lancet 2009 374 9692 796 806 2-s2.0-69449101785 10.1016/S0140-6736(09)60918-1
39. Eron J. J., Young B., Cooper D. A., Youle M., DeJesus E., Andrade-Villanueva J., Workman C., Zajdenverg R., Fätkenheuer G., Berger D. S., Kumar P. N., Rodgers A. J., Shaughnessy M. A., Walker M. L., Barnard R. J., Miller M. D., DiNubile M. J., Nguyen B.-Y., Leavitt R., Xu X., Sklar P., Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir- based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. The Lancet 2010 375 9712 396 407 2-s2.0-75149175071 10.1016/S0140- 6736(09)62041-9
40. Lake J. E., McComsey G. A., Hulgan T. M., Wanke C. A., Mangili A., Walmsley S. L., Boger M. S., Turner R. R., McCreath H. E., Currier J. S., A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care and STDs 2012 26 9 532 540 2-s2.0-84865459534 10.1089/apc.2012.0135
41. ACTG Metabolic Study Group Procedures for Measurement of Circumferences
42. 2-isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Radical Biology and Medicine 2013 59 36 44 2-s2.0-84876473977 10.1016/j.freeradbiomed.2012.09.030
43. Rho Y. H., Chung C. P., Oeser A., Solus J. F., Gebretsadik T., Shintani A., Raggi P., Milne G. L., Stein C. M., Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care and Research 2010 62 10 1473 1480 2-s2.0-77957662965 10.1002/acr.20237
44. Avalos I., Chung C. P., Oeser A., Milne G. L., Borntrager H., Morrow J. D., Raggi P., Solus J., Stein C. M., Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Lupus 2007 16 12 981 986 2-s2.0-37849016152 10.1177/0961203307083313
45. Lake J. E., McComsey G. A., Hulgan T., Wanke C., Mangili A., Soluble CD14 declines in virologically suppressed women switching from protease inhibitor or NNRTI to raltegravir: the women, integrase, and fat accumulation trial. Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections 2013 Atlanta, Ga, USA
46. Silva E. F., Charreau I., Gourmel B., Mourah S., Kalidi I., Guillon B., De Castro N., Caron F., Braun J., Molina J.-M., Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. Journal of Infectious Diseases 2013 208 6 892 897 2-s2.0-84883225615 10.1093/infdis/jit280
47. 2-isoprostanes and coronary artery calcification: the CARDIA study. Clinical Chemistry 2005 51 1 125 131 2-s2.0-11144285386 10.1373/clinchem.2004.037630 (Pubitemid 40024021)
48. Eikelboom J. W., Hirsh J., Weitz J. I., Johnston M., Yi Q., Yusuf S., Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 105 14 1650 1655 2-s2.0-0037046196 10.1161/01.CIR.0000013777.21160.07 (Pubitemid 34298607)
49. Breyer R. M., Bagdassarian C. K., Myers S. A., Breyer M. D., Prostanoid receptors: subtypes and signaling. Annual Review of Pharmacology and Toxicology 2001 41 661 690 2-s2.0-0035042253 10.1146/annurev.pharmtox.41.1.661 (Pubitemid 32385902)
50. 2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prevention Research 2013 6 6 511 518 2-s2.0-84878887971 10.1158/1940-6207.CAPR-13-0040
51. 2 metabolite and risk for colorectal adenoma. Cancer Prevention Research 2012 5 2 336 342 2-s2.0-84863279448 10.1158/1940-6207.CAPR-11-0426
52. 2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiology Biomarkers and Prevention 2009 18 11 3075 3078 2-s2.0-72749110291 10.1158/1055-9965.EPI-09-0680
53. Kekatpure V. D., Boyle J. O., Zhou X. K., Duffield-Lillico A. J., Gross N. D., Lee N. Y., Subbaramaiah K., Morrow J. D., Milne G., Lippman S. M., Dannenberg A. J., Elevated levels of urinary prostaglandin E metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prevention Research 2009 2 11 957 965 2-s2.0-74049117079 10.1158/1940-6207.CAPR-09-0093
54. Sabin C. A., Worm S. W., Weber R., Reiss P., El-Sadr W., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. The Lancet 2008 371 9622 1417 1426 10.1016/S0140-6736(08)60423-7
55. Ribaudo H. J., Benson C. A., Zheng Y., Koletar S. L., Collier A. C., Lok J. J., Smurzynski M., Bosch R. J., Bastow B., Schouten J. T., No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clinical Infectious Diseases 2011 52 7 929 940 2-s2.0-79953731529 10.1093/cid/ciq244
56. Satchell C. S., O'Halloran J. A., Cotter A. G., Peace A. J., O'Connor E. F., Tedesco A. F., Feeney E. R., Lambert J. S., Sheehan G. J., Kenny D., Mallon P. W. G., Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. Journal of Infectious Diseases 2011 204 8 1202 1210 2-s2.0-80052885199 10.1093/infdis/jir509
57. Falcinelli E., Francisci D., Belfiori B., Petito E., Guglielmini G., Malincarne L., Mezzasoma A., Sebastiano M., Conti V., Giannini S., Bonora S., Baldelli F., Gresele P., In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thrombosis and Haemostasis 2013 110 2 349 357 2-s2.0-84880842075 10.1160/TH12-07-0504
58. Schoembaum E. E., Hartel D., Lo Y., Howard A. A., Floris-Moore M., Arnsten J. H., Santoro M., HIV infection, drug use, and onset of natural menopause. Clinical Infectious Diseases 2005 41 10 1517 1524 2-s2.0-27644512336 10.1086/497270 (Pubitemid 41579999)